MOUNJARO® 12.5mg KwikPen®, 1 Stk.

What is MOUNJARO® 12.5mg KwikPen®

MOUNJARO® 12.5mg KwikPen® is a multi-dose, pre-filled injection device delivering 12.5 mg tirzepatide in 0.6 mL once weekly. This strength is used as an intermediate escalation dose between 10 mg and 15 mg, ensuring gradual and tolerable titration for patients. Each KwikPen® contains 2.4 mL of solution (total 50 mg tirzepatide) and provides four fixed doses. The solution is a clear, colourless to slightly yellow liquid, administered subcutaneously into the abdomen, thigh, or upper arm.

• Per dose: 12.5 mg tirzepatide (0.6 mL)

• Total pen content: 50 mg/2.4 mL (20.8 mg/mL)

• Number of doses: 4

• Injection sites: Abdomen, thigh, upper arm

• Device type: Disposable, multi-dose pen

What is the Administration Protocol for MOUNJARO® 12.5mg KwikPen®

The 12.5 mg strength is typically prescribed as a step-up dose for patients requiring further glycaemic or weight management. Weekly administration is consistent and structured to maintain therapeutic effect.

• Initiation: Start at 2.5 mg weekly for 4 weeks, increase stepwise in 2.5 mg increments

• Titration: 12.5 mg used as an escalation step before maximum 15 mg dose

• Maintenance options: 5 mg, 10 mg, 12.5 mg, or 15 mg weekly

• Missed dose protocol:

  • If ≤4 days late: administer promptly

  • If >4 days late: skip and continue with scheduled regimen

• Injection technique:

  • Attach a sterile needle before use

  • Dial to 1 (0.6 mL full dose)

  • Inject subcutaneously, hold for 5 seconds until dose window reads 0

• Rotate injection sites to reduce irritation

What are the Indications for MOUNJARO® 12.5mg KwikPen®

MOUNJARO® is indicated for use in adults requiring improved glycaemic regulation and structured weight management. Contraindications and cautions should be observed.

• Indications:

  • Treatment of adults with type 2 diabetes mellitus as monotherapy or with other agents

  • Weight management in adults with BMI ≥30 kg/m²

  • Adults with BMI ≥27 to <30 kg/m² plus comorbidities (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes)

• Contraindications:

  • Hypersensitivity to tirzepatide or formulation excipients

• Precautions:

  • History of pancreatitis

  • Severe gastrointestinal disease such as gastroparesis

• Adverse effects:

  • Common: Nausea, vomiting, diarrhoea, abdominal pain, constipation

  • Hypoglycaemia risk increased with insulin or sulphonylurea use

  • Mild injection-site reactions

  • Occasional gallbladder events

  • Rare: acute pancreatitis, hypersensitivity reactions

What is the composition of MOUNJARO® 12.5mg KwikPen®

Each dose contains tirzepatide as the active ingredient and specific excipients for stability and delivery.

• Active substance: Tirzepatide 12.5 mg/0.6 mL

• Total pen content: 50 mg/2.4 mL

• Concentration: 20.8 mg/mL

• Excipients: Disodium hydrogen phosphate heptahydrate, benzyl alcohol (~5.4 mg per dose), glycerol, phenol, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections

• Sodium content: <1 mmol sodium per dose (sodium-free)

• Appearance: Clear, colourless to slightly yellow solution

What Comes in the MOUNJARO® 12.5mg KwikPen® Package

The packaging provides the KwikPen® device and documentation, but does not include needles.

• Presentation: Pre-filled KwikPen® with 2.4 mL solution (4 doses)

• Pack sizes: 1 or 3 pens per carton (availability may vary)

• Needles: Not supplied with pack; must be purchased separately

• Documentation: Patient Information Leaflet (PIL) and Instructions for Use (IFU)

Does MOUNJARO® 12.5mg KwikPen® cause side effects?

Adverse reactions can occur, most often gastrointestinal in origin, with dose-dependent frequency.

• Very common: Nausea, diarrhoea, vomiting, abdominal pain, constipation

• Hypoglycaemia: Higher incidence with concomitant insulin or sulphonylureas

• Injection-site reactions: Mild to moderate, up to 8% of patients

• Gallbladder events: Occur in up to 2% of patients

• Uncommon but serious: Acute pancreatitis

• Rare: Hypersensitivity reactions including angioedema and anaphylaxis

• Laboratory findings: Increases in amylase and lipase observed

How should MOUNJARO® 12.5mg KwikPen® be stored?

Adherence to proper storage conditions preserves product efficacy and sterility.

• Unopened pens: Refrigerate at 2–8 °C

• Do not freeze; discard if frozen

• After first use: Store at ≤30 °C for up to 30 days

• Discard after 30 days, regardless of residual solution

• Needles: Remove after each use; discard in a sharps container

• Keep out of reach of children